Shopping Cart
- Remove All
- Your shopping cart is currently empty
K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity. K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 1-2 weeks | |
50 mg | $2,180 | 1-2 weeks | |
100 mg | $2,800 | 1-2 weeks |
Description | K145 is inactive against SphK1 and other protein kinases. K145 induces cell apoptosis and has potently antitumor activity. K145 is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM. |
Targets&IC50 | SPHK2:(ki)6.4 µM , SPHK2:4.3 µM |
In vitro | K145 (10 μM; 24 hours; U937 cells) treatment significantly induces apoptosis in U937 cells. K145 (4-8 μM; 3 hours; U937 cells) treatment decreases the phosphorylation of ERK and Akt. Treatment with K145 (10 μM) causes a decrease of total cellular S1P without significant effects on ceramide levels.K145 (0-10 μM; 24-72 hours; U937 cells) treatment significantly inhibits the growth of U937 cells in a concentration-dependent manner. |
In vivo | K145 treatment significantly inhibits the growth of U937 tumors in nude mice. |
Molecular Weight | 348.46 |
Formula | C18H24N2O3S |
Cas No. | 1309444-75-4 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.